<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148261</url>
  </required_header>
  <id_info>
    <org_study_id>53325</org_study_id>
    <nct_id>NCT04148261</nct_id>
  </id_info>
  <brief_title>Epinephrine and Cortisol in Depression</brief_title>
  <official_title>The Effects of Epinephrine and Cortisol on Emotion in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effects of two hormones called epinephrine and cortisol on how
      the brain processes emotional material using functional MRI to measure brain activity. The
      study hopes to learn how epinephrine and cortisol affect the brain differently in depressed
      and non-depressed individuals.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sadness-induced subgenual cingulate activity as measured by functional magnetic resonance imaging</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Healthy Arm, CORT + EPI, then PLB + EPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy participant will receive cortisol pill and epinephrine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Arm, PLB + EPI, then CORT + EPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy participant will receive placebo pill and epinephrine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depression Arm, CORT + EPI, then PLB + EPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depressed participant will receive cortisol pill and epinephrine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depression Arm, PLB + EPI, then CORT + EPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depressed participant will receive placebo pill and epinephrine infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone Acetate (CORT)</intervention_name>
    <description>Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg</description>
    <arm_group_label>Depression Arm, CORT + EPI, then PLB + EPI</arm_group_label>
    <arm_group_label>Healthy Arm, CORT + EPI, then PLB + EPI</arm_group_label>
    <other_name>Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine Sulfate (EPI)</intervention_name>
    <description>Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min</description>
    <arm_group_label>Depression Arm, CORT + EPI, then PLB + EPI</arm_group_label>
    <arm_group_label>Depression Arm, PLB + EPI, then CORT + EPI</arm_group_label>
    <arm_group_label>Healthy Arm, CORT + EPI, then PLB + EPI</arm_group_label>
    <arm_group_label>Healthy Arm, PLB + EPI, then CORT + EPI</arm_group_label>
    <other_name>Adrenalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PLB)</intervention_name>
    <description>Participants will receive a placebo</description>
    <arm_group_label>Depression Arm, PLB + EPI, then CORT + EPI</arm_group_label>
    <arm_group_label>Healthy Arm, PLB + EPI, then CORT + EPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight of less than 280 pounds

          -  HAM-D Score of greater than 7 for depression participants

        Exclusion Criteria:

          -  Psychotropic medications

          -  Recent surgery

          -  Endocrine disorders

          -  Liver disease

          -  Kidney disease

          -  Thyroid disorder

          -  History of malaria

          -  Tuberculosis

          -  Osteoporosis

          -  Glaucoma or cataracts

          -  Chronic expressed infections (herpes, HIV, etc)

          -  History of congestive heart failure

          -  History of recurring seizures

          -  Stomach ulcers

          -  Comorbid psychosis

          -  Current use of illicit drugs

          -  Diabetes

          -  Any cardiovascular disease (angina, hypovolemia, coronary artery disease, low/high
             blood pressure, etc)

          -  Any pulmonary disease

          -  Any cerebrovascular disease

          -  Sulfate hypersensitivity

          -  Glaucoma

          -  Infection

          -  Pregnancy

          -  Parkinson's Disease

          -  Panic Disorder

          -  Over 280 pounds in weight

          -  In-dwelling ferrous metals

          -  Left handed

          -  Abnormal hearing

          -  Claustrophobic

          -  Head injury with loss of consciousness

          -  Active suicidal ideation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Sudheimer, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keith Sudheimer, Ph.D.</last_name>
    <phone>(650) 701-3674</phone>
    <email>ksudheim@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dalton Duvio, B.A.</last_name>
    <phone>(650) 427-9091</phone>
    <email>dlduvio@stanford.edu</email>
  </overall_contact_backup>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Keith Sudheimer</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

